1. ‘Sustained remission’ in a case of SLE following megadose cyclophosphamide.
- Author
-
Mittal, G., Balakrishna, C., Mangat, G., and Joshi, V.R.
- Subjects
SYSTEMIC lupus erythematosus ,KIDNEY diseases ,PHOSPHAMIDON ,PATIENTS - Abstract
Cytotoxic therapy, especially with cyclophosphamide in the dose 8–20 mg/kg used as intermittent pulses, has been shown to improve both patient and renal survival in systematic lupus erythematosus (SLE), but to date there is no cure for the disease. Owing to the paucity of recognisable clones, the rationale and goal of cytotoxic immunosuppressive therapy in the treatment of immune-mediated diseases as against malignancies is to suppress the aberrant inflammation and immune-mediated reactions responsible for tissue damage, without dangerously suppressing the normal host defence mechanism(s). We report the case of a patient suffering from SLE with nephritis who has remained in sustained remission over the past 8 years without any maintenance therapy following an accidental administration of a single dose of 5000 mg of intravenous cyclophosphamide (44.2 mg/kg body weight). The patient recovered fully from pancytopenia following the injection. Presently, she is asymptomatic and working gainfully. Her laboratory parameters including blood counts, urine analysis, FANA and anti-dsDNA have reverted to normal. Cyclophosphamide in the dose of 30–160 mg/kg has been safely and effectively used in various neoplastic conditions with the aim of destroying every possible tumour cell. The experience of the present case suggests that such an approach may be applicable to SLE. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF